Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)

view original post

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGRResearch Report) and BioNTech SE (BNTXResearch Report) with bullish sentiments.

Voyager Therapeutics (VYGR)

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Voyager Therapeutics, with a price target of $14.00. The company’s shares closed last Wednesday at $6.69, close to its 52-week low of $5.71.

According to TipRanks.com, Kulkarni is a 5-star analyst with an average return of 11.3% and a 42.5% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, ACADIA Pharmaceuticals, and Bioxcel Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Voyager Therapeutics with a $18.00 average price target, representing a 156.4% upside. In a report issued on November 1, TD Cowen also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

BioNTech SE (BNTX)

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE today and set a price target of $137.00. The company’s shares closed last Wednesday at $111.48.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 11.3% and a 43.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Syndax Pharmaceuticals, and Bristol-Myers Squibb.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $137.36 average price target, representing a 29.8% upside. In a report issued on October 31, Canaccord Genuity also maintained a Buy rating on the stock with a $171.00 price target.

Read More on VYGR: